**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 70166

**Manuscript Type:** CASE REPORT

**Is *de novo* membranous nephropathy suggestive of alloimmunity in renal transplantation? A case report**

Darji PI *et al*. Case report of *de novo* membranous nephropathy

Prakash I Darji, Himanshu A Patel, Bhavya P Darji, Ajay Sharma, Ahmed Halawa

**Prakash I Darji, Himanshu A Patel,** Department of Nephrology and Renal Transplantation, Zydus Hospitals, Ahmedabad 380059, Gujarat, India

**Bhavya P Darji,** Internship, Department of Medicine, GCS Medical College, Hospital and Research Centre, Ahmedabad 380025, Gujarat, India

**Ajay Sharma, Ahmed Halawa,** Faculty of Health and Life Science, Institute of Learning and Teaching, University of Liverpool, Liverpool L69 3BX, United Kingdom

**Ajay Sharma,** Consultant Transplant Surgeon, Royal Liverpool University Hospitals, Liverpool L7 8XP, United Kingdom

**Ahmed Halawa,** Department of Transplantation, Sheffield Teaching Hospitals, Sheffield S10 2JF, United Kingdom

**Author contributions:** Darji P conceptualized the study; Patel H contributed to writing the paper; Darji B contributed to writing and revising the paper; Sharma A and Halawa A contributed intellectual discussion and expertise to the study; and all authors reviewed and approved the final manuscript.

**Corresponding author: Ahmed Halawa, FRCS (Gen Surg), MD, MSc, Surgeon,** Department of Transplantation, Sheffield Teaching Hospitals, Glossop Rd, Sheffield S10 2JF, United Kingdom. ahmed.halawa@liverpool.ac.uk

**Received:** July 26, 2021

**Revised:** December 8, 2021

**Accepted:** January 6, 2022

**Published online:** January 18, 2022

**Abstract**

BACKGROUND

Post-transplant nephrotic syndrome (PTNS) in a renal allograft carries a 48% to 77% risk of graft failure at 5 years if proteinuria persists. PTNS can be due to either recurrence of native renal disease or *de novo* glomerular disease. Its prognosis depends upon the underlying pathophysiology. We describe a case of post-transplant membranous nephropathy (MN) that developed 3 mo after kidney transplant. The patient was properly evaluated for pathophysiology, which helped in the management of the case.

CASE SUMMARY

This 22-year-old patient had chronic pyelonephritis. He received a living donor kidney, and human leukocyte antigen-DR (HLA-DR) mismatching was zero. PTNS was discovered at the follow-up visit 3 mo after the transplant. Graft histopathology was suggestive of MN. In the past antibody-mediated rejection (ABMR) might have been misinterpreted as *de novo* MN due to the lack of technologies available to make an accurate diagnosis. Some researchers have observed that HLA-DR is present on podocytes causing an anti-DR antibody deposition and development of *de novo* MN. They also reported poor prognosis in their series. Here, we excluded the secondary causes of MN. Immunohistochemistry was suggestive of IgG1 deposits that favoured the diagnosis of *de novo* MN. The patient responded well to an increase in the dose of tacrolimus and angiotensin converting enzyme inhibitor.

CONCLUSION

Exposure of hidden antigens on the podocytes in allografts may have led to subepithelial antibody deposition causing *de novo* MN.

**Key Words:** Post-transplant nephrotic syndrome; Recurrent membranous nephropathy; Secondary membranous nephropathy; Alloimmunity; Cryptic antigens; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Darji PI, Patel HA, Darji BP, Sharma A, Halawa A. Is *de novo* membranous nephropathy suggestive of alloimmunity in renal transplantation? A case report. *World J Transplant* 2022; 12(1): 15-20

**URL:** https://www.wjgnet.com/2220-3230/full/v12/i1/15.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v12.i1.15

**Core Tip:** This is a case presentation of a patient who developed post-transplant nephrotic syndrome 3 mo after transplantation and was diagnosed with *de* *novo* membranous nephropathy (MN). He had received a well-matched living donor kidney. According to the literature, the most common causes of *de* *novo* MN include secondary causes and antibody mediated injury, which we ruled out. This patient was treated with increased dosage of tacrolimus and an angiotensin converting enzyme inhibitor, which resulted in a good recovery. We favoured a new concept of pathogenesis of *de* *novo* MN, which requires the identification of the causative antigens.

**INTRODUCTION**

The development of proteinuria after kidney transplantation is not uncommon, with 3% to 14% of recipients presenting with post-transplant nephrotic syndrome (PTNS). The risk of allograft loss with persistent proteinuria at 5 years is around 48% to 77%[1].This may be due to either a recurrence or new (*de novo*) development of glomerular disease. It is rather difficult to differentiate between these two possibilities because only 15% to 20% of native kidneys are subjected to biopsy before transplantation[2]. Factors, such as immunosuppression, donor specific anti-human leukocyte antigen (HLA) antibodies (DSA), acute rejection, hypertension and infection, might pose a diagnostic dilemma in regard to the clinical picture and histopathology of the graft. We hereby present a case of a kidney transplant patient who developed PTNS in the early period following transplantation.

**CASE PRESENTATION**

***Chief complaints***

There were no chief complaints. Abnormal signs were observed at the 3-mo follow-up after renal transplantation.

***History of present illness***

A 22-year-old male patient was diagnosed with end-stage kidney disease due to chronic pyelonephritis and received dialysis for 8 mo. He received a live donor kidney transplant from his 42-year-old mother in August 2020. HLA-A, B and DR mismatches were 1-1-0. He was not given induction therapy and was maintained on triple immunosuppression (tacrolimus, mycophenolate mofetil and prednisolone). He was discharged on day 7 with a serum creatinine of 0.9 mg/dL (normal: 0.7-1.2 mg/dL). His graft duplex scan was normal, and tacrolimus 12-h trough level was maintained at 10 ng/mL. At the time of discharge, his urine protein was normal. At the 3-mo follow-up, he had signs of mild pedal oedema.

***History of past illness***

The patient had a history of end-stage kidney disease due to chronic pyelonephritis treated with a renal transplantation 3 mo prior. A bilateral ureteric re-implantation for vesicoureteral reflux had been performed at the age of 6 years.

***Personal and family history***

No significant personal and family history.

***Physical examination***

We observed mild pedal oedema, which was pitting in nature.

***Laboratory examinations***

His urine showed + 4 proteinuria, and urine protein/creatinine ratio was 4.6 mg/mg (normal: < 0.2 mg/mg) with stable serum creatinine. We recorded a serum albumin level of 3 gm/dL and total cholesterol of 295 mg/dL, suggestive of PTNS.

***Imaging examinations***

Allograft biopsy was performed and subjected to light, immunofluorescence and electron microscopy to rule out secondary causes of PTNS. Light microscopy revealed a thickening of the basement membrane and spikes at high power magnification with periodic acid-Schiff silver methenamine stain (Figures 1A and 1B). Immunofluorescence microscopy showed IgG deposits along the glomerular basement membrane in a granular pattern (Figure 2), suggesting membranous nephropathy (MN).

**Evaluation and differential diagnosis**

This was a case of PTNS that was histologically suggestive of MN. We conducted further investigations to identify secondary causes of MN, antibody-mediated rejection (ABMR), and differentiation of recurrence *vs* *de novo* MN.

This patient’s serology was negative for hepatitis B virus, hepatitis C virus and hepatitis E virus. Cytomegalovirus was also undetected by polymerase chain reaction. Antiphospholipase A2 receptor antibody testing was negative. There was no evidence of post-transplant malignancy upon clinical assessment and detailed investigations. Secondary causes of MN were ruled out.

In this recipient, the donor class II HLA was fully matched. When he developed proteinuria, DSA was negative. His biopsy did not show any changes of ABMR. Electron microscopy did not show duplication of peritubular capillaries or glomerular basement membrane (Figure 3). The C4d stain was also negative (Figure 4). These findings ruled out ABMR in our case.

The biopsy revealed positive IgG1 deposits and scarcity of IgG4 after immunohistochemistry (Figures 5A and 5B).

**FINAL DIAGNOSIS**

Post kidney transplant *de novo* MN.

**TREATMENT**

The patient’s tacrolimus 12-h trough level at the time of development of PTNS was 5.9 ng/mL. The dose of tacrolimus was increased to achieve a level of 9-12 ng/mL. Ramipril was commenced and optimized to 5 mg twice a day. Serum creatinine and potassium were checked on day 10 and remained unchanged. The dose of ramipril was kept tolerable to avoid hypotension.

**OUTCOME AND FOLLOW-UP**

At 6 mo after the biopsy, his urine protein creatinine ratio decreased to 0.6 mg/mg. His graft function remained stable with a serum creatinine level of 0.94 mg/dL.

**DISCUSSION**

Recurrence of idiopathic MN after renal transplant is seen in 25%-40% of cases. A diagnosis of *de novo* MN is reported in 1%-2% of post-transplant adults and up to 9% in paediatric renal transplant recipients[3]. The exact incidence is difficult to ascertain due to variability in pretransplant biopsies to confirm diagnosis[2,4].

New onset hepatitis virus infection, particularly hepatitis C virus and hepatitis B virus, is a common secondary cause of *de novo* MN[2,3,5]. Taton *et* *al*[5] reported a probable association of hepatitis E virus infection with post renal transplant *de novo* MN.Teixeira *et* *al*[6] reported a case of cytomegalovirus infection and its relationship to *de novo* MN. Risk factors such as post-transplant malignancy, ureteral obstruction and renal infarction have also been found to cause *de novo* MN[2]. Prasad *et* *al*[7] reported a case of *de novo* MN in a patient having Alport’s syndrome as a native kidney disease. It has been reported that *de novo* MN is more common in patients with IgA nephropathy[2,3,7]. We ruled out all the secondary causes of MN in our patient.

Sometimes, a recurrence of MN may be misdiagnosed as *de novo* MN due to undiagnosed native kidney disease[2,4]. Pathology findings of *de novo* MN are like those of idiopathic MN, except for mesangial proliferation, focal and segmental distribution of subepithelial deposits, and simultaneous presence of different stages of disease in *de* *novo* MN[3]. Anti-phospholipase A2 receptor antibodies have been identified in most cases of idiopathic MN, whereas anti-phospholipase A2 receptor antibodies are absent in *de novo* MN because of other causative antigens that remain unidentified[2,3,8-10]. Different IgG subtype depositions have been reported in cases of primary/recurrent MN and *de novo* MN. IgG4 was commonly deposited in recurrent MN, whereas IgG1 was observed in *de novo* MN. In our case, there was an absence of anti-phospholipase A2 receptor antibodies and IgG1 deposition in the kidney biopsy, which confirmed the diagnosis of *de novo* MN.

Schwarz *et* *al*[11] published a retrospective observational study of renal transplant subjects transplanted between 1970 and 1992 who developed *de novo* MN. They observed histopathological features of acute vascular rejection in 17 out of 21 recipients and interstitial rejection in 12 out of 21 recipients. During this period, the availability of DSA measurement techniques and knowledge of diagnosing ABMR may have been limited. Other investigators have reported a possible relationship of donor-specific alloantibodies in the development of *de novo* MN[12]. Wen *et* *al*[13] reported the presence of HLA-DR on podocytes of recipients who developed *de novo* MN; they also reported a higher incidence of peritubular capillaritis, intimal arteritis and C4d deposits in post-transplant MN in comparison to recurrence of idiopathic MN in the renal allograft. There are also reports of poor prognoses in patients who had *de novo* MN possibly related to ABMR[11,12]. Interestingly, Bansal *et* *al*[14] reported a case of *de novo* MN following a renal transplant between conjoined twins. Even in our case, the mother was the donor, with fully matching HLA-DR. The biopsy of our patient confirmed that there were no changes suggestive of acute or chronic ABMR.

There may be another pathophysiological mechanism precipitating in the development of *de novo* MN. It is likely that immunological, viral, mechanical or ischemic injury to the graft may expose the podocyte cryptic antigens to the recipient immune system. This may trigger an activation of innate immunity, resulting in production of auto- or alloantibodies against the antigens on the podocyte. This antigen-antibody complex develops at subepithelial sites and causes activation of complement and membrane injury[9].

There is lack of consensus in the published literature about the optimal management of *de novo* MN. Schwarz *et* *al*[11] reported no response to methylprednisolone bolus and a high graft loss. El Kossi *et* *al*[12] hypothesized that *de novo* MN was an atypical manifestation of ABMR. If a secondary cause, such as viral infection or malignancy, is identified, then the treatment of the underlying cause might treat MN. Cyclophosphamide or rituximab has been tried, as in the treatment of idiopathic MN[8]. In our case, we optimized the dose of tacrolimus and started an angiotensin converting enzyme inhibitor; the proteinuria was significantly reduced, and graft function was stable after 6 mo, suggesting a good prognosis.

**CONCLUSION**

*De novo* MN, a rare disease in renal allografts, may be due to exposure of a hidden antigen on the podocytes that is recognized by the immune system of the recipient. The causative antigens still need to be identified. The reported poor prognosis of *de novo* MN may be due to misdiagnosed ABMR, as it was in an era prior to routine availability of DSA by the Luminex platform (Bio-Rad Laboratories, Hercules, CA, United States) and recognition of C4d for an ABMR diagnosis. Proper evaluation and targeting of the pathophysiological processes may help in the management of these patients.

**REFERENCES**

1 **Leon J**, Pérez-Sáez MJ, Batal I, Beck LH Jr, Rennke HG, Canaud G, Legendre C, Pascual J, Riella LV. Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management. *Transplantation* 2019; **103**: 1990-2002 [PMID: 31568231 DOI: 10.1097/TP.0000000000002758]

2 **Ponticelli C**, Moroni G, Glassock RJ. De novo glomerular diseases after renal transplantation. *Clin J Am Soc Nephrol* 2014; **9**: 1479-1487 [PMID: 24700797 DOI: 10.2215/CJN.12571213]

3 **Ponticelli C**, Glassock RJ. De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease? *Transpl Int* 2012; **25**: 1205-1210 [PMID: 22909324 DOI: 10.1111/j.1432-2277.2012.01548.x]

4 **Abbas F**, El Kossi M, Jin JK, Sharma A, Halawa A. Recurrence of primary glomerulonephritis: Review of the current evidence. *World J Transplant* 2017; **7**: 301-316 [PMID: 29312859 DOI: 10.5500/wjt.v7.i6.301]

5 **Taton B**, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, Pommereau A, Ronco P, Kamar N, Merville P, Couzi L. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. *Transpl Infect Dis* 2013; **15**: E211-E215 [PMID: 24103101 DOI: 10.1111/tid.12143]

6 **Teixeira e Costa F**, Pinto JR, Carvalho F, Galvão MJ. An early case of de novo membranous nephropathy in a renal transplant patient. *Transplant Proc* 2002; **34**: 364 [PMID: 11959328 DOI: 10.1016/s0041-1345(01)02803-2]

7 **Prasad GV**, Sweet JM, Cole EH, Cardella CJ. Allograft de novo membranous nephropathy complicating Alport's syndrome. *Nephron* 2000; **86**: 227 [PMID: 11015013 DOI: 10.1159/000045762]

8 **Alsharhan L**, Beck LH Jr. Membranous Nephropathy: Core Curriculum 2021. *Am J Kidney Dis* 2021; **77**: 440-453 [PMID: 33487481 DOI: 10.1053/j.ajkd.2020.10.009]

9 **Batal I**, Vasilescu ER, Dadhania DM, Adel AA, Husain SA, Avasare R, Serban G, Santoriello D, Khairallah P, Patel A, Moritz MJ, Latulippe E, Riopel J, Khallout K, Swanson SJ, Bomback AS, Mohan S, Ratner L, Radhakrishnan J, Cohen DJ, Appel GB, Stokes MB, Markowitz GS, Seshan SV, De Serres SA, Andeen N, Loupy A, Kiryluk K, D'Agati VD. Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. *Am J Kidney Dis* 2020; **76**: 374-383 [PMID: 32359820 DOI: 10.1053/j.ajkd.2020.01.009]

10 **Mubarak M**. Does idiopathic imply autoimmune causation in membranous nephropathy? A new twist in the aetiopathogenesis of the disease. *Port J Nephrol Hypert* 2015; **29**: 266-268

11 **Schwarz A**, Krause PH, Offermann G, Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. *Transplantation* 1994; **58**: 650-654 [PMID: 7940683]

12 **El Kossi M**, Harmer A, Goodwin J, Wagner B, Shortland J, Angel C, McKane W. De novo membranous nephropathy associated with donor-specific alloantibody. *Clin Transplant* 2008; **22**: 124-127 [PMID: 18217914 DOI: 10.1111/j.1399-0012.2007.00741.x]

13 **Wen J**, Xie K, Zhang M, Chen J, Zhang J, Cheng D, Li X, Ji S, Liu Z. HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy. *Medicine (Baltimore)* 2016; **95**: e4809 [PMID: 27631233 DOI: 10.1097/MD.0000000000004809]

14 **Bansal VK**, Kozeny GA, Fresco R, Vertuno LL, Hano JE. De novo membranous nephropathy following renal transplantation between conjoint twins. *Transplantation* 1986; **41**: 404-406 [PMID: 3513400]

**Footnotes**

**Informed consent statement:** Written consent was obtained from the patient in their native language.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 26, 2021

**First decision:** October 27, 2021

**Article in press:** January 6, 2022

**Specialty type:** Transplantation

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Mubarak M **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ


**Figure Legends**




**Figure 1 Light microscopy.** A:Haematoxylin and eosin staining (40 ×magnification)showeddiffusethickening ofthe glomerular basement membrane; B: Periodic acid-Schiff silver methenamine stain (100 × magnification) showed membrane thickening.




**Figure 2 Immunofluorescence microscopy showed granular IgG deposits in the glomerular basement membrane.**



**Figure 3 Electron microscopy showed subepithelial electron dense deposit s (× 13500).**



**Figure 4 Immunohistochemistry (10 × magnification) was negative for C4d stain.**



**Figure 5 Immunohistochemistry staining (40 × magnification).** A: IgG4 was negative; B: IgG1 was positive.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**